| Betterment Mental Health Counseling, Inc. | |
|
4242 S Tamiami Trl Venice FL 34293-5105 | |
| (941) 800-4924 | |
| (941) 837-2480 |
| Full Name | Betterment Mental Health Counseling, Inc. |
|---|---|
| Speciality | Clinic/Center |
| Location | 4242 S Tamiami Trl, Venice, Florida |
| Authorized Official Name and Position | Patrick M Ewing (OFFICE MANAGER, VICE PRESIDENT) |
| Authorized Official Contact | 9418004924 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Betterment Mental Health Counseling, Inc. 4242 S Tamiami Trl Venice FL 34293-5105 Ph: (941) 800-4924 | Betterment Mental Health Counseling, Inc. 4242 S Tamiami Trl Venice FL 34293-5105 Ph: (941) 800-4924 |
| NPI Number | 1235716630 |
|---|---|
| Provider Enumeration Date | 03/24/2021 |
| Last Update Date | 01/18/2024 |
| Certification Date | 01/18/2024 |
| Medicare PECOS PAC ID | 6709249642 |
|---|---|
| Medicare Enrollment ID | O20230825001031 |
News Archive
Breast cancer treatments such as Herceptin that target a marker called HER2 have dramatically improved outcomes for women with this type of cancer. But nearly half of these cancers are resistant to Herceptin from the start and almost all of them will eventually become resistant.
An international study led by scientists from the Crick Institute in London and the Hebrew University of Jerusalem revealed a survival mechanism in cancer cells that allows the disease to erupt again even after aggressive treatment.
MedGenesis Therapeutix Inc. ("MedGenesis"), a biopharmaceutical company developing and commercializing innovative treatments for patients with serious central nervous system (CNS) diseases, announced today that it has successfully entered into an agreement with Amgen Inc. ("Amgen"), granting MedGenesis an exclusive, worldwide license for glial cell line-derived neurotrophic factor (GDNF) protein in CNS and non-CNS indications, subject to the rights of a co-exclusive licensee for CNS indications in certain countries, as further described below.
Interventions that improve nutrition and environmental conditions can also provide substantial gains toward the goal of reducing child mortality, especially when the interventions prioritize the poor, according to a study in the October 24/31 issue of JAMA, a theme issue on poverty and human development.
The U.K. Government and the Bill & Melinda Gates Foundation with UNFPA and other partners on Wednesday, July 11, are hosting the London Summit on Family Planning, which aims "to raise $4 billion to expand access to contraception for 120 million women in the developing world by 2020," according to Reuters. At the summit, the Gates Foundation "is set to unveil funding a sum in the hundreds of millions of dollars for a campaign to improve access to contraception in the developing world," the news service notes.
› Verified 9 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235716630 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QM0801X | Clinic/center - Mental Health (including Community Mental Health Center) | (* (Not Available)) | Primary |
| Provider Name | Waleska Acevedo |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1871858175 PECOS PAC ID: 0840410635 Enrollment ID: I20140929002493 |
News Archive
Breast cancer treatments such as Herceptin that target a marker called HER2 have dramatically improved outcomes for women with this type of cancer. But nearly half of these cancers are resistant to Herceptin from the start and almost all of them will eventually become resistant.
An international study led by scientists from the Crick Institute in London and the Hebrew University of Jerusalem revealed a survival mechanism in cancer cells that allows the disease to erupt again even after aggressive treatment.
MedGenesis Therapeutix Inc. ("MedGenesis"), a biopharmaceutical company developing and commercializing innovative treatments for patients with serious central nervous system (CNS) diseases, announced today that it has successfully entered into an agreement with Amgen Inc. ("Amgen"), granting MedGenesis an exclusive, worldwide license for glial cell line-derived neurotrophic factor (GDNF) protein in CNS and non-CNS indications, subject to the rights of a co-exclusive licensee for CNS indications in certain countries, as further described below.
Interventions that improve nutrition and environmental conditions can also provide substantial gains toward the goal of reducing child mortality, especially when the interventions prioritize the poor, according to a study in the October 24/31 issue of JAMA, a theme issue on poverty and human development.
The U.K. Government and the Bill & Melinda Gates Foundation with UNFPA and other partners on Wednesday, July 11, are hosting the London Summit on Family Planning, which aims "to raise $4 billion to expand access to contraception for 120 million women in the developing world by 2020," according to Reuters. At the summit, the Gates Foundation "is set to unveil funding a sum in the hundreds of millions of dollars for a campaign to improve access to contraception in the developing world," the news service notes.
› Verified 9 days ago
| Provider Name | Hallie Rebecca Talov |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1295089696 PECOS PAC ID: 7315295086 Enrollment ID: I20180813001989 |
News Archive
Breast cancer treatments such as Herceptin that target a marker called HER2 have dramatically improved outcomes for women with this type of cancer. But nearly half of these cancers are resistant to Herceptin from the start and almost all of them will eventually become resistant.
An international study led by scientists from the Crick Institute in London and the Hebrew University of Jerusalem revealed a survival mechanism in cancer cells that allows the disease to erupt again even after aggressive treatment.
MedGenesis Therapeutix Inc. ("MedGenesis"), a biopharmaceutical company developing and commercializing innovative treatments for patients with serious central nervous system (CNS) diseases, announced today that it has successfully entered into an agreement with Amgen Inc. ("Amgen"), granting MedGenesis an exclusive, worldwide license for glial cell line-derived neurotrophic factor (GDNF) protein in CNS and non-CNS indications, subject to the rights of a co-exclusive licensee for CNS indications in certain countries, as further described below.
Interventions that improve nutrition and environmental conditions can also provide substantial gains toward the goal of reducing child mortality, especially when the interventions prioritize the poor, according to a study in the October 24/31 issue of JAMA, a theme issue on poverty and human development.
The U.K. Government and the Bill & Melinda Gates Foundation with UNFPA and other partners on Wednesday, July 11, are hosting the London Summit on Family Planning, which aims "to raise $4 billion to expand access to contraception for 120 million women in the developing world by 2020," according to Reuters. At the summit, the Gates Foundation "is set to unveil funding a sum in the hundreds of millions of dollars for a campaign to improve access to contraception in the developing world," the news service notes.
› Verified 9 days ago
| Provider Name | Barbara Angela Morelli |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1952381998 PECOS PAC ID: 3173970811 Enrollment ID: I20231116003643 |
News Archive
Breast cancer treatments such as Herceptin that target a marker called HER2 have dramatically improved outcomes for women with this type of cancer. But nearly half of these cancers are resistant to Herceptin from the start and almost all of them will eventually become resistant.
An international study led by scientists from the Crick Institute in London and the Hebrew University of Jerusalem revealed a survival mechanism in cancer cells that allows the disease to erupt again even after aggressive treatment.
MedGenesis Therapeutix Inc. ("MedGenesis"), a biopharmaceutical company developing and commercializing innovative treatments for patients with serious central nervous system (CNS) diseases, announced today that it has successfully entered into an agreement with Amgen Inc. ("Amgen"), granting MedGenesis an exclusive, worldwide license for glial cell line-derived neurotrophic factor (GDNF) protein in CNS and non-CNS indications, subject to the rights of a co-exclusive licensee for CNS indications in certain countries, as further described below.
Interventions that improve nutrition and environmental conditions can also provide substantial gains toward the goal of reducing child mortality, especially when the interventions prioritize the poor, according to a study in the October 24/31 issue of JAMA, a theme issue on poverty and human development.
The U.K. Government and the Bill & Melinda Gates Foundation with UNFPA and other partners on Wednesday, July 11, are hosting the London Summit on Family Planning, which aims "to raise $4 billion to expand access to contraception for 120 million women in the developing world by 2020," according to Reuters. At the summit, the Gates Foundation "is set to unveil funding a sum in the hundreds of millions of dollars for a campaign to improve access to contraception in the developing world," the news service notes.
› Verified 9 days ago
| Provider Name | Maria T Ewing |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1710974126 PECOS PAC ID: 7517320450 Enrollment ID: I20240227003303 |
News Archive
Breast cancer treatments such as Herceptin that target a marker called HER2 have dramatically improved outcomes for women with this type of cancer. But nearly half of these cancers are resistant to Herceptin from the start and almost all of them will eventually become resistant.
An international study led by scientists from the Crick Institute in London and the Hebrew University of Jerusalem revealed a survival mechanism in cancer cells that allows the disease to erupt again even after aggressive treatment.
MedGenesis Therapeutix Inc. ("MedGenesis"), a biopharmaceutical company developing and commercializing innovative treatments for patients with serious central nervous system (CNS) diseases, announced today that it has successfully entered into an agreement with Amgen Inc. ("Amgen"), granting MedGenesis an exclusive, worldwide license for glial cell line-derived neurotrophic factor (GDNF) protein in CNS and non-CNS indications, subject to the rights of a co-exclusive licensee for CNS indications in certain countries, as further described below.
Interventions that improve nutrition and environmental conditions can also provide substantial gains toward the goal of reducing child mortality, especially when the interventions prioritize the poor, according to a study in the October 24/31 issue of JAMA, a theme issue on poverty and human development.
The U.K. Government and the Bill & Melinda Gates Foundation with UNFPA and other partners on Wednesday, July 11, are hosting the London Summit on Family Planning, which aims "to raise $4 billion to expand access to contraception for 120 million women in the developing world by 2020," according to Reuters. At the summit, the Gates Foundation "is set to unveil funding a sum in the hundreds of millions of dollars for a campaign to improve access to contraception in the developing world," the news service notes.
› Verified 9 days ago
News Archive
Breast cancer treatments such as Herceptin that target a marker called HER2 have dramatically improved outcomes for women with this type of cancer. But nearly half of these cancers are resistant to Herceptin from the start and almost all of them will eventually become resistant.
An international study led by scientists from the Crick Institute in London and the Hebrew University of Jerusalem revealed a survival mechanism in cancer cells that allows the disease to erupt again even after aggressive treatment.
MedGenesis Therapeutix Inc. ("MedGenesis"), a biopharmaceutical company developing and commercializing innovative treatments for patients with serious central nervous system (CNS) diseases, announced today that it has successfully entered into an agreement with Amgen Inc. ("Amgen"), granting MedGenesis an exclusive, worldwide license for glial cell line-derived neurotrophic factor (GDNF) protein in CNS and non-CNS indications, subject to the rights of a co-exclusive licensee for CNS indications in certain countries, as further described below.
Interventions that improve nutrition and environmental conditions can also provide substantial gains toward the goal of reducing child mortality, especially when the interventions prioritize the poor, according to a study in the October 24/31 issue of JAMA, a theme issue on poverty and human development.
The U.K. Government and the Bill & Melinda Gates Foundation with UNFPA and other partners on Wednesday, July 11, are hosting the London Summit on Family Planning, which aims "to raise $4 billion to expand access to contraception for 120 million women in the developing world by 2020," according to Reuters. At the summit, the Gates Foundation "is set to unveil funding a sum in the hundreds of millions of dollars for a campaign to improve access to contraception in the developing world," the news service notes.
› Verified 9 days ago
Centerpointe Counseling And Recovery Of Sarasota Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 425 Commercial Ct, Siute 100, Venice, FL 34292 Phone: 941-488-4811 Fax: 941-488-4899 | |
Gulf Coast Neurology Associates Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 600 Nokomis Ave S, Suite 204, Venice, FL 34285 Phone: 941-486-6600 Fax: 941-486-6610 | |
Venice Counseling Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 333 Tamiami Trl S Ste 260, Venice, FL 34285 Phone: 941-237-7174 | |
Center For Family & Personal Growth Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 417 Commercial Ct, Suite E, Venice, FL 34292 Phone: 941-485-8896 Fax: 941-485-8935 | |
Neurologic Consultants, Pa Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 517 Riviera St, Suite A, Venice, FL 34285 Phone: 941-412-1208 Fax: 941-412-1248 | |
Neurology Associates-tonya Stephenson, Md Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 517d Riviera St, Venice, FL 34285 Phone: 941-248-5196 | |
Eagle's Wings Counseling Center, Inc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 405 Commercial Ct Ste E, Venice, FL 34292 Phone: 941-375-4321 Fax: 941-375-4096 |